Description: BMI Vaccine
vaccine (299) polio (75) poliovirus (2) polio vaccine (2) ultraipv
BMI Vaccines, a vaccine design and development company, has addressed key barriers to polio eradication through the development of ultra IPV™ , an efficacious, inexpensive, safe to manufacture, easy to administer and thermostable inactivated polio vaccine. ultra IPV™ is based on an innovative process utilizing ultra-violet light to create an effective inactivated polio vaccine.
Contact BMI: Email: [email protected] Phone: (301) 378-2551 Info: Download White Paper
Poliovirus consists of three serotypes (PV1, PV2, and PV3) and is stable in the environment. In regions where the virus is present, failure to vaccinate leads inevitably to polio outbreaks. Global eradication is complete for PV2 and PV3 and is close for PV1. Currently, infections from vaccine-derived viruses outnumber those from wild viruses. Once eradication is complete, world-wide vaccine vigilance will be needed for at least two decades to maintain a polio-free world.